Drug Discovery

ViiV Healthcare, Halozyme partner to develop HIV medicines

ViiV Healthcare has signed a global collaboration and license agreement with Halozyme Therapeutics to develop “ultra-long-acting” medicines for HIV.

Arrowhead, Horizon sign collaboration deal for RNAi therapeutic development

Arrowhead Pharmaceuticals has signed a global collaboration and license agreement with Horizon Therapeutics for the development of RNA interference (RNAi) therapeutic, ARO-XDH.

MorphoSys agrees to acquire Constellation Pharmaceuticals for $1.7bn

German company MorphoSys has signed a definitive agreement to acquire US-based Constellation Pharmaceuticals for approximately $1.7bn.

Amgen, Kyowa Kirin partner to develop antibody for atopic dermatitis

Amgen has signed an agreement with Japanese pharmaceutical firm Kyowa Kirin to jointly develop and commercialise Phase III-ready antibody for treating atopic dermatitis.

Pieris and Genentech to develop respiratory and ophthalmology therapies

Biotechnology company Pieris Pharmaceuticals has signed a multi-programme research collaboration and licence agreement with Roche Group subsidiary Genentech.

Exscientia expands AI-based drug discovery alliance with BMS

Exscientia and Bristol-Myers Squibb agree to leverage AI to discover drug candidates for various diseases.

Lilly, MiNA Therapeutics partner to develop new drug candidates

Eli Lilly and Company and MiNA Therapeutics are set to develop new drug candidates as part of a global research collaboration.

Pfizer acquires Amplyx Pharmaceuticals

Pharmaceutical company Pfizer has acquired a privately held company Amplyx Pharmaceuticals for an undisclosed amount.

Vertex and Obsidian partner to discover gene-editing medicines

Vertex Pharmaceuticals and Obsidian Therapeutics have established a multi-year collaboration for the discovery of new treatments that regulate gene editing.